In short
Murcidencel, also known as an autologous dendritic cell vaccine producing interleukin-12, is being studied in clinical trials for children, adolescents, and young adults with progressive, recurrent, or primarily metastatic high-risk tumors. This innovative therapy aims to harness the power of the patient's own immune system to fight cancer cells. The ongoing research focuses on assessing the safety and efficacy of this treatment in combination with other therapies for patients who have not responded well to standard treatments.
At a glance
- Drug Name
- Murcidencel (Autologous dendritic cell vaccine producing interleukin-12)
- Trial Category
- Category 2 (Integrated Phase I and Phase II)
- Target Population
- Children, adolescents, and young adults with progressive, recurrent, or primarily metastatic high-risk tumors
- Primary Objective
- Assessment of safety through monitoring of Adverse Events of Special Interest (AESI)
- Secondary Objectives
- Time to progression, overall survival, objective response rate, clinical benefit rate
- Administration
- Intradermal injection
- Key Inclusion Criteria
- Confirmed diagnosis of refractory or relapsing high-risk tumor, adequate organ function, performance status ≥ 50 (Karnofsky/Lansky)
- Key Exclusion Criteria
- Untreated autoimmune disease, previous treatment with autologous dendritic cell vaccine, uncontrolled hypertension, pregnancy
What is MURCIDENCEL?
MURCIDENCEL is an innovative medical treatment being studied for children, teenagers, and young adults with certain types of difficult-to-treat cancers. It's also known by other names such as Canpuldencel-T, DCVax-L, or "autologous dendritic cells pulsed with autologous tumour cell lysate". This treatment is classified as a type of cell therapy, which means it uses cells from the patient's own body to fight cancer.
How Does MURCIDENCEL Work?
MURCIDENCEL is made from special cells called dendritic cells that are taken from the patient's own body. These cells are a crucial part of our immune system. In the laboratory, scientists modify these dendritic cells to produce a substance called interleukin-12, which helps stimulate the immune system to fight cancer. The modified cells are then given back to the patient as an injection under the skin (intradermal use).
This treatment is designed to help the patient's own immune system recognize and attack cancer cells more effectively. It's a form of immunotherapy, which is a cutting-edge approach to treating cancer.
Who Might Benefit from MURCIDENCEL?
MURCIDENCEL is being studied for young patients with high-risk pediatric malignancies that are: Progressive (continuing to grow despite treatment) Recurrent (have come back after initial treatment) Primarily metastatic (have spread to other parts of the body at the time of diagnosis)
These are typically cancers that have not responded well to standard treatments and have a poor outlook with current therapies. Specifically, the study is looking at cancers where the expected 5-year survival rate is less than 25% with standard treatments.
Current Clinical Trial
MURCIDENCEL is currently being tested in a clinical trial. This trial is combining MURCIDENCEL with other cancer treatments to see if it can improve outcomes for patients with these difficult-to-treat cancers.
The main goal of this trial is to assess how safe MURCIDENCEL is when used in combination with other treatments. Researchers will be closely monitoring for any side effects, especially those that are considered "adverse events of special interest".
Eligibility for the Trial
To participate in this trial, patients must meet certain criteria. Some key points include: Having a confirmed diagnosis of a high-risk tumor that hasn't responded to standard treatments Being in relatively good overall health (able to perform daily activities) Having adequate function of bone marrow, kidneys, liver, and heart Not having certain other health conditions like uncontrolled autoimmune diseases or psychiatric diagnoses
It's important to note that there are additional specific medical criteria that doctors will use to determine if a patient is eligible for the trial.
Safety and Effectiveness Measures
During the trial, researchers will be looking at several factors to determine how well MURCIDENCEL works and how safe it is. These include: How often certain side effects occur How long it takes for the cancer to progress How long patients survive overall How many patients see their tumors shrink or disappear How many patients experience any benefit from the treatment
These measures will help doctors understand if MURCIDENCEL is safe and effective for treating these challenging cancers in young patients.